Published in Int J STD AIDS on September 01, 2010
Performance of HSV-2 type specific serological tests in men in Kenya. J Virol Methods (2009) 0.91
Light microscopy, culture, molecular, and serologic methods for detection of herpes simplex virus. J Clin Microbiol (2013) 0.90
Prevalence and incidence estimation of HSV-2 by two IgG ELISA methods among South African women at high risk of HIV. PLoS One (2015) 0.81
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev (2016) 0.80
Incident HSV-2 infections are common among HIV-1-discordant couples. J Infect Dis (2013) 0.78
Sero-prevalence of herpes simplex type 2 virus (HSV-2) and HIV infection in Kampala, Uganda. Afr Health Sci (2014) 0.78
Genital infections and risk of premature rupture of membranes in Mulago Hospital, Uganda: a case control study. BMC Res Notes (2015) 0.77
Comparative performance of the Uni-Gold™ HSV-2 Rapid: a point-of-care HSV-2 diagnostic test in unselected sera from a reference laboratory. J Clin Virol (2014) 0.76
Precision of the Kalon Herpes Simplex Virus Type 2 IgG ELISA: an international inter-laboratory assessment. BMC Infect Dis (2015) 0.75
HSV-2 acquisition among HIV-1 infected adults treated with tenofovir as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study. J Infect Dis (2017) 0.75
Evaluation of Herpes Simplex Virus Type 2 Serological Tests for Use With Dried Blood Spots in Kenya. Sex Transm Dis (2017) 0.75
Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial. Reprod Health (2017) 0.75
Serologic screening for herpes simplex virus type 2 in persons with human immunodeficiency virus. Am J Med Sci (2013) 0.75
Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J Infect Dis (2017) 0.75
Performance of Kalon herpes simplex virus 2 assay using dried blood spots among young women in Uganda. Afr J Lab Med (2016) 0.75
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 13.32
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med (2007) 7.79
Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med (2008) 7.49
Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis (2001) 6.35
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis (2007) 4.52
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med (2000) 4.39
Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med (1995) 4.03
Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One (2008) 3.94
Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol (2004) 3.36
Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect (2004) 3.27
Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis (1998) 2.72
Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol (2004) 2.55
Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ (2004) 1.95
Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis (2003) 1.92
Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda. Clin Vaccine Immunol (2008) 1.89
Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis (2002) 1.75
Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med (1995) 1.70
Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis (2004) 1.54
Performance and use of HSV type-specific serology test kits. Herpes (2002) 1.51
Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect Dis (2005) 1.34
Synergistic interactions between herpes simplex virus type-2 and human immunodeficiency virus epidemics. Herpes (2004) 1.30
Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western blot and inhibition testing. Sex Transm Infect (2008) 1.26
Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. Drugs (2007) 1.02
Mucosal shedding of human herpesvirus 8 in men. N Engl J Med (2000) 6.59
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol (1996) 4.81
HIV viral load markers in clinical practice. Nat Med (1996) 4.78
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA (2003) 4.38
The establishment of imitation and its use for the development of complex behavior in schizophrenic children. Behav Res Ther (1967) 4.02
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis (1998) 2.98
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69
Sensitivity and specificity of fluorescence microscopy for diagnosing pulmonary tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis (2009) 2.68
Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS (1998) 2.53
Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis (1989) 2.41
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis (1994) 2.26
The core proteins of 35S hnRNP complexes. Characterization of nine different species. Eur J Biochem (1985) 2.17
Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (1999) 1.94
Elimination and reintroduction of primary and secondary syphilis. Am J Public Health (1999) 1.91
Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis (2000) 1.90
Rectal microbicides for U.S. gay men. Are clinical trials needed? Are they feasible? HIVNET Vaccine Preparedness Study Protocol Team. Sex Transm Dis (1998) 1.81
Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle. Sex Transm Infect (2004) 1.81
A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.74
High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am J Epidemiol (2006) 1.70
Cryptosporidium infection and CD4 counts. Ann Intern Med (1992) 1.64
Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics. J Clin Microbiol (1998) 1.58
Assessment of the validity and utility of a sleep-symptom questionnaire. Am J Respir Crit Care Med (1994) 1.58
Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis (2001) 1.58
To notify or not to notify: STD patients' perspectives of partner notification in Seattle. Sex Transm Dis (2000) 1.49
Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr (2001) 1.48
Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis (1999) 1.48
Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses (2006) 1.47
Angiotensin II receptor blocker induced fetopathy: 7 cases. Klin Padiatr (2011) 1.46
Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis (2001) 1.43
Upper extremity kinematics and body roll during preferred-side breathing and breath-holding front crawl swimming. J Sports Sci (1999) 1.40
An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis (2011) 1.37
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis (2001) 1.34
The diagnosis of childhood tuberculosis in an HIV-endemic setting and the use of induced sputum. Int J Tuberc Lung Dis (2005) 1.34
Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment. J Infect Dis (1998) 1.33
Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country. Int J Tuberc Lung Dis (2006) 1.31
Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr (2001) 1.29
Relationship between sleepiness and general health status. Sleep (1996) 1.26
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1994) 1.22
Comparison of diploid fibroblast and rabbit kidney tissue cultures and a diploid fibroblast microtiter plate system for the isolation of herpes simplex virus. J Clin Microbiol (1988) 1.18
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda. Int J Antimicrob Agents (2001) 1.17
Perspective: validating surrogate markers--are we being naive? J Infect Dis (1997) 1.16
Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med (2000) 1.15
Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis (1991) 1.15
Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother (1983) 1.15
Efficacy of patient-delivered partner medication in the treatment of sexual partners in Uganda. Sex Transm Dis (2001) 1.13
Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis (1996) 1.12
Risk factors for HIV-1 shedding in semen. Am J Epidemiol (1999) 1.12
HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. Sex Transm Infect (2006) 1.09
Routine typing of herpes simplex virus isolates. Diagn Microbiol Infect Dis (1985) 1.07
Relative prevalence of methicilline resistant Staphylococcus aureus and its susceptibility pattern in Mulago Hospital, Kampala, Uganda. Tanzan J Health Res (2009) 1.06
Micronutrient supplements and mortality of HIV-infected adults with pulmonary TB: a controlled clinical trial. Int J Tuberc Lung Dis (2007) 1.05
Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr (1999) 1.03
Total asymmetric synthesis of the putative structure of the cytotoxic diterpenoid (-)-sclerophytin a and of the authentic natural sclerophytins A and B. J Am Chem Soc (2001) 1.03
Burkitt's lymphoma in Kenya: geographical, age, gender and ethnic distribution. East Afr Med J (2004) 1.03
Adult Burkitt's lymphoma in patients with and without human immunodeficiency virus infection in Kenya. Int J Cancer (2001) 1.02
Factors influencing sexual partner referral for sexually transmitted diseases in Uganda. Sex Transm Dis (1999) 1.01
Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clin Microbiol Infect (2006) 1.00
Leaf k interaction with water stress inhibition of nonstomatal-controlled photosynthesis. Plant Physiol (1985) 0.99
Kaposi's sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya. Ann Trop Med Parasitol (2005) 0.99
Fear, anxiety and perceived control in children of agoraphobic parents. J Child Psychol Psychiatry (1996) 0.98
Water birth and infection in babies. BMJ (1994) 0.97
Percutaneous computed tomography-guided stabilization of posterior pelvic fractures. Clin Orthop Relat Res (1994) 0.96
Acute infection of Macaca nemestrina by human immunodeficiency virus type 1. Virology (1993) 0.96
Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis (1994) 0.94
Directional limits on persistent gravitational waves using LIGO S5 science data. Phys Rev Lett (2011) 0.93
Campylobacter spp among children with acute diarrhea attending Mulago hospital in Kampala--Uganda. Afr Health Sci (2009) 0.92
Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother (1997) 0.91
Molecular characterisation of Mycobacterium bovis isolates from cattle carcases at a city slaughterhouse in Uganda. Vet Rec (2009) 0.91
Reduction of postoperative CT artifacts of pelvic fractures by use of titanium implants. Orthopedics (1990) 0.91
Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration. J Clin Epidemiol (1998) 0.89
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol (2011) 0.88
Activation of beta-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis (2001) 0.88
Community-acquired pneumonia in Ugandan adults: short-term parenteral ampicillin therapy for bacterial pneumonia. Am J Trop Med Hyg (2001) 0.87
Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda. Int J Tuberc Lung Dis (2013) 0.86
The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda. Int J Epidemiol (1999) 0.86
Percutaneous CT-guided stabilization of complex sacroiliac joint disruption with threaded compression bars. Orthopedics (1992) 0.85
Impedance imaging in the newborn. Clin Phys Physiol Meas (1987) 0.85
Soluble IL-2 receptor beta and gamma subunits: ligand binding and cooperativity. Eur Cytokine Netw (1994) 0.85
Anatomical and radiological considerations in compressive bar technique for posterior pelvic disruptions. J Orthop Trauma (1991) 0.85
Assessment of the teratogenic potential of piperonyl butoxide, biphenyl, and phosalone in the rat. Toxicol Appl Pharmacol (1979) 0.84
Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. Sex Transm Dis (2007) 0.84
Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents. Pediatr Infect Dis J (2001) 0.83
Sexual and demographic determinants for herpes simplex virus type 2 among fishermen along Lake Victoria, Kenya. Sex Transm Infect (2007) 0.82
Efficacy of waiting periods and topical fluoride treatment on toothbrush abrasion of eroded enamel in situ. Caries Res (2007) 0.82
Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.82
A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol (2009) 0.81
Congenital renal tubular dysplasia and skull ossification defects similar to teratogenic effects of angiotensin converting enzyme (ACE) inhibitors. J Med Genet (1997) 0.81
Amylin peptide is increased in preterm neonates with feed intolerance. Arch Dis Child Fetal Neonatal Ed (2008) 0.81
Vomitoxin (4-deoxynivalenol): effects on reproduction of mice and rats. Toxicol Appl Pharmacol (1984) 0.80
Risk factors associated with permanent access-site infections in chronic hemodialysis patients. Infect Control Hosp Epidemiol (1997) 0.80
Photodynamic inactivation of free and cell-associated HIV-1 using the photosensitizer, benzoporphyrin derivative. J Acquir Immune Defic Syndr (1994) 0.80
Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. East Afr Med J (1997) 0.80
Cloning of the rat insulin-like growth factor binding protein-1 gene and analysis of its 5' promoter region. Biochem Biophys Res Commun (1992) 0.79
Embryotoxicity of 4-deoxynivalenol (vomitoxin) in mice. Bull Environ Contam Toxicol (1982) 0.79
Contribution of different placental cells to the expression and stimulation of antimicrobial proteins (AMPs). Placenta (2011) 0.79
Analysis of the TK enzyme complex induced by HSV types 1 and 2 by means of isoelectric focusing and polyacrylamide gel electrophoresis. Arch Virol (1982) 0.79
Echovirus encephalitis/myositis in X-linked agammaglobulinemia. N Engl J Med (1985) 0.78